204078-86-4

Basic information

• Product Name: 2-(IsobutylaMino)benzonitrile
• Synonyms: 2-(IsobutylaMino)benzonitrile
• CAS NO: 204078-86-4
• Molecular Formula: C₁₁H₁₄N₂
• Molecular Weight: 174.24226
• Mol File: 204078-86-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(IsobutylaMino)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(IsobutylaMino)benzonitrile(204078-86-4)
• EPA Substance Registry System: 2-(IsobutylaMino)benzonitrile(204078-86-4)

Safety Data

• Hazardous Substances Data: 204078-86-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(Isobutylamino)benzonitrile is used as an antihistamine medication for treating allergic conditions such as hay fever and hives. It is effective in blocking the effects of histamine, which is responsible for causing allergic symptoms, thus providing relief to the patients.
Used in Over-the-Counter Medications:
2-(Isobutylamino)benzonitrile is used as an active ingredient in over-the-counter allergy medications, making it easily accessible for individuals seeking relief from mild to moderate allergy symptoms without a prescription.
Used in Prescription Medications:
In cases where allergy symptoms are more severe or persistent, 2-(Isobutylamino)benzonitrile is used as a prescription medication, allowing for a more controlled and monitored treatment plan under the guidance of a healthcare professional.

Upstream product

• 55305-43-6 N-cyano-N-phenyl-p-toluenesulfonamide 
• 394-47-8 2-fluorobenzonitrile 
• 78-81-9 isobutylamine 

Relevant articles and documents

Rhodium(III)-Catalyzed Direct Cyanation of Aromatic C-H Bond to Form 2-(Alkylamino)benzonitriles Using N-Nitroso As Directing Group

2-(Alkylamino)benzonitriles were synthesized via a rhodium-catalyzed cyanation on the aryl C-H bond and subsequent denitrosation of N-nitrosoarylamines using a removable nitroso as the directing group, in which N-cyano-N-phenyl-p-methylbenzenesulfonamide (NCTS) was used as the "CN" source. Various substituents on the aryl ring and amino group of N-nitrosoarylamines tolerated the reaction, and the corresponding products were achieved in moderate to good yields.

Method of inhibiting neoplastic cells with imidazoquinazoline derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to imidazoquinazoline derivatives.

Imidazoquinazoline derivatives

PCT No. PCT/JP97/03023 Sec. 371 Date Apr. 27, 1998 Sec. 102(e) Date Apr. 27, 1998 PCT Filed Aug. 29, 1997 PCT Pub. No. WO98/08848 PCT Pub. Date Mar. 5, 1998Imidazoquinoline derivatives of the formula (wherein X may be O or S) provide selective cyclic guanosine 3',5' monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitory activity. The compounds are useful for treating or ameliorating cardiovascular disease such as thrombosis, angina pectoris, hypertension, heart failure and arterial sclerosis, as well as asthma, impotence and the like.